The Medicines Company, a biopharmaceutical company, focuses on developing therapeutics for the treatment of therosclerotic cardiovascular disease. The company is developing Inclisiran, an investigational RNA interference therapeutic that inhibits production of proprotein convertase subtilisin/kexin type 9, which controls LDL-cholesterol levels. It has collaboration agreement with Alnylam Pharmaceuticals, Inc The Medicines Company was founded in 1996 and is headquartered in Parsippany, New Jersey.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
Phone973-290-6000
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$6.14 million
Profitability
Miscellaneous
Employees62
Next Earnings Date11/14/2019 (Estimated)
OptionableOptionable
The Medicines (NASDAQ:MDCO) Frequently Asked Questions
What is The Medicines' stock symbol?
The Medicines trades on the NASDAQ under the ticker symbol "MDCO."
How were The Medicines' earnings last quarter?
The Medicines Company (NASDAQ:MDCO) announced its earnings results on Wednesday, July, 24th. The company reported ($0.71) earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($0.73) by $0.02. During the same period last year, the company earned ($0.63) EPS. View The Medicines' Earnings History.
When is The Medicines' next earnings date?
What price target have analysts set for MDCO?
14 Wall Street analysts have issued 12-month target prices for The Medicines' stock. Their predictions range from $48.00 to $145.00. On average, they expect The Medicines' share price to reach $73.33 in the next twelve months. This suggests a possible upside of 28.7% from the stock's current price. View Analyst Price Targets for The Medicines.
What is the consensus analysts' recommendation for The Medicines?
14 Wall Street analysts have issued "buy," "hold," and "sell" ratings for The Medicines in the last year. There are currently 2 hold ratings and 12 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for The Medicines.
Has The Medicines been receiving favorable news coverage?
Media headlines about MDCO stock have trended somewhat negative this week, according to InfoTrie Sentiment Analysis. The research firm identifies positive and negative media coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. The Medicines earned a media sentiment score of -1.5 on InfoTrie's scale. They also assigned media coverage about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the company's share price in the near term. View News Stories for The Medicines.
Are investors shorting The Medicines?
The Medicines saw a increase in short interest in the month of September. As of September 30th, there was short interest totalling 24,350,000 shares, an increase of 5.6% from the August 30th total of 23,050,000 shares. Based on an average trading volume of 2,080,000 shares, the short-interest ratio is currently 11.7 days. Approximately 32.2% of the shares of the stock are short sold. View The Medicines' Current Options Chain.
Who are some of The Medicines' key competitors?
Some companies that are related to The Medicines include Merck KGaA (MKGAF), UCB (UCBJF), GRIFOLS S A/S (GRFS), Genmab A/S (GNMSF), BioMarin Pharmaceutical (BMRN), Array Biopharma (ARRY), Elanco Animal Health (ELAN), Mylan (MYL), Ono Pharmaceutical (OPHLF), Alnylam Pharmaceuticals (ALNY), GALAPAGOS NV/S (GLPG), Teva Pharmaceutical Industries (TEVA), Ionis Pharmaceuticals (IONS), Bausch Health Companies (BHC) and SAGE Therapeutics (SAGE).
What other stocks do shareholders of The Medicines own?
Who are The Medicines' key executives?
The Medicines' management team includes the folowing people:
- Mr. Mark Timney, CEO & Director (Age 54)
- Mr. Christopher J. Visioli, CFO & Treasurer (Age 43)
- Mr. Stephen M. Rodin J.D., Exec. VP, Gen. Counsel & Sec. (Age 43)
- Dr. Clive A. Meanwell, Chief Innovation Officer & Director (Age 61)
- Dr. Goutham Krishna Gorti, VP & Head of Investor Relations
Who are The Medicines' major shareholders?
The Medicines' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Rhenman & Partners Asset Management AB (0.19%), Bailard Inc. (0.08%), CIBC Private Wealth Group LLC (0.07%), State of Alaska Department of Revenue (0.07%), Nelson Van Denburg & Campbell Wealth Management Group LLC (0.02%) and Assenagon Asset Management S.A. (0.02%). Company insiders that own The Medicines stock include Alexander J Denner, Armin M Kessler, Christopher T Cox, Clive Meanwell, Fredric N Eshelman, Mark Timney, Melvin K Spigelman, Stephen M Rodin and William Crouse. View Institutional Ownership Trends for The Medicines.
Which major investors are selling The Medicines stock?
Which major investors are buying The Medicines stock?
MDCO stock was bought by a variety of institutional investors in the last quarter, including CIBC Private Wealth Group LLC, State of Alaska Department of Revenue, Assenagon Asset Management S.A., Envestnet Asset Management Inc., Meeder Asset Management Inc., Nelson Van Denburg & Campbell Wealth Management Group LLC, Nisa Investment Advisors LLC and Zurcher Kantonalbank Zurich Cantonalbank . Company insiders that have bought The Medicines stock in the last two years include Alexander J Denner, Christopher T Cox, Fredric N Eshelman and Mark Timney. View Insider Buying and Selling for The Medicines.
How do I buy shares of The Medicines?
Shares of MDCO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is The Medicines' stock price today?
One share of MDCO stock can currently be purchased for approximately $56.99.
How big of a company is The Medicines?
The Medicines has a market capitalization of $4.52 billion and generates $6.14 million in revenue each year. The company earns $-123,160,000.00 in net income (profit) each year or ($2.91) on an earnings per share basis. The Medicines employs 62 workers across the globe.View Additional Information About The Medicines.
What is The Medicines' official website?
How can I contact The Medicines?
The Medicines' mailing address is 8 SYLVAN WAY, PARSIPPANY NJ, 07054. The company can be reached via phone at 973-290-6000 or via email at [email protected]
MarketBeat Community Rating for The Medicines (NASDAQ MDCO)
MarketBeat's community ratings are surveys of what our community members think about The Medicines and other stocks. Vote "Outperform" if you believe MDCO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MDCO will underperform the S&P 500 over the long term. You may vote once every thirty days.
